Arama

EISSN 2148-5607

TJG IS INDEXED IN WEB OF SCIENCE AND PUBMED IMPACT FACTOR: 1.2

Turkish Journal of Gastroenterology

PDF

HIGHLY CITED ARTICLES

HBV and HCV are the risk factors in CCA

Tan et al.

Serum resolvin levels in irritable bowel syndrome

Karatay and Gül Utku

Microbial improvement after intervention

Qian et al.

18F-FDGPET/CT in gallbladder carcinoma

Arslan et al.

Bezoar in endoscopy

Gökbulut et al.

Effect of vitamin D on CD40L gene expression in UC

Sharifi et al.

ERCP for acute cholangitis

Khamaysi and Taha

Inborn metabolic causes of fatty liver disease

Yıldız and Sivri

Gastric and small intestinal TSA

Kiremitci et al.

COVID-19 in Hepatology and Liver transplantation

Kabaçam et al.

All Title Keyword Full Text DOI

Authors

Article Type

Article Category

Year

Search Results

Total of 10 results

Ranking

Release Date Sort Sort Article Type

Incidence rate of anemia in inflammatory bowel diseases

Özlen Atuğ, Haluk Tarık Kani, Munkhtsetseg Banzragch, Neşe İmeryüz, Hakan Akın

(Turk J Gastroenterol 2016; 27: 143-148) DOI: 10.5152/tjg.2016.16011

Abstract Full Text ( PDF) Related Articles

Should we use proton pump inhibitors as an add-on treatment in hereditary hemochromatosis?

Haluk Tarık Kani , Feyza Gündüz

(Turk J Gastroenterol 2018; 29: 253-253) DOI: 10.5152/tjg.2018.17713

Abstract Full Text ( PDF) Related Articles

Covering the Cover

Haluk Tarık Kani

(Turk J Gastroenterol 2019; 30: 664-666) DOI: 10.5152/tjg.2019.070819

Abstract Full Text ( PDF) Related Articles

Incidence rate of anemia in inflammatory bowel diseases

Should we use proton pump inhibitors as an add-on treatment in hereditary hemochromatosis?

Covering the Cover

Evaluation of depression, anxiety and quality of life in hepatitis C patients who treated with direct acting antiviral agents

Effect of carbon dioxide versus room air insufflation on post-colonoscopic pain: A prospective, randomized, controlled study

Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience

Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease

Biologic Therapy Carries a Very Low Risk of Reactivation in Hepatitis B Surface Antigen-Negative Phase of Hepatitis B

RE: Risk of HBV Reactivation in HBsAg Negative and AntiHBc IgG Positive Patients Receiving Biologic Therapy

Are Cross-Sectional Imaging Modalities Enough for Sarcopenia Assessment?